The authors have stated explicitly that there are no conflicts of interest in connection with this article. Conclusions. Widespread use of combination antiretroviral therapy (cART) and systematic cervical screening has reduced the rate of abnormal PAP smears. It seems feasible to identify low-risk women by combining HIV-related information and PAP smear results. Screening low-risk women living with HIV at three-year intervals similar to HIV-negative women appears justified.
Introduction
The Centers for Disease Control and Prevention classified invasive cervical cancer (ICC) as an AIDS-defining illness in 1993 after it was shown that HIV-positive women have a markedly increased prevalence of cervical squamous intraepithelial lesions (SIL) and ICC (1) . Since the introduction of combination antiretroviral therapy (cART) in the mid 1990s, the incidence of the two other AIDS-defining malignancies (Kaposi's sarcoma and nonHodgkin's lymphoma) has substantially decreased. The incidence of ICC, however, has not decreased during the cART era (2) (3) (4) .
Invasive cervical cancer develops through a transitional process from human papilloma virus (HPV)-induced cervical lesions. Detection of the earlier stages of HPV-related cervical disease via organized screening programs has decreased the incidence of ICC in the general population. However, women living with HIV have increased acquisition, decreased clearance and therefore an increased prevalence of oncogenic HPV infection compared with HIV-negative women (5) . Moreover, they are often infected by multiple HPV types (6) . Because of the higher incidence and prevalence of SIL and increased risk of progression to ICC in women living with HIV vs. HIV-negative women (7, 8) , most HIV treatment guidelines have traditionally recommended cervical screening by means of annual Papanicolaou (PAP) smears.
In 2012 the US consensus guidelines for HIV negative women recommended either cytology every 3 years or co-testing (PAP smear and HPV-DNA testing) every 5 years in women ≥30 years old (9) (10) (11) . New recommendations were supported by Dinkelspiel et al. showing that no difference existed when comparing the rates of cervical cancer in women of this age screened either annually with PAP smears in 2000 or with co-testing every 3 years in 2009 (12) .
After new recommendations for HIV-negative women, the US Department of Health and Human Services (DHHS) (13) and the European AIDS Clinical Society (14) revised their guidelines to recommend screening every 1-3 years, even though there are limited data to support these changes. In the DHHS guidelines, co-testing is recommended in order to identify women at low risk of SIL.
In the present study we examined the prevalence and risk factors of HPV-related cervical disease among a carefully monitored group of HIV-infected women screened by means of annual PAP smear samples during the era of modern cART. In addition, we used the data to evaluate whether the recently recommended less frequent PAP screening would be sufficient in low-risk women when co-testing for HPV-DNA is not in routine use.
Material and methods
This retrospective study included all 389 HIV-infected women who had paid at least two visits to the Department of Infectious Diseases, Helsinki University Hospital, between 2002 and 2013.
All HIV-infected women are referred to the Department of Obstetrics and Gynecology, Helsinki University Hospital, for gynecological follow up and an annual PAP smear after their first visit to the HIV clinic. Nineteen women who did not attend cervical screening at our institution during the study years and one woman who had been diagnosed with ICC before the study period were excluded from the study (Figure 1 ).
Cervical cytological findings were interpreted using the 1991 Bethesda System criteria as normal, atypical squamous cells of undetermined significance (ASC-US), lowgrade squamous intraepithelial lesions (LSIL), atypical squamous cells -cannot exclude HSIL (ASC-H), highgrade squamous intraepithelial lesions (HSIL) and atypical glandular cells (AG-NOS). If there was more than one PAP smear per calendar year, only the first one was included in the study. All women with abnormal cytological findings underwent control smears, colposcopy, biopsy and treatment according to Finnish cervical cancer screening guidelines (15) .
The following information was collected from the hospital's patient records: year of birth, year of HIV diagnosis and route of HIV-transmission, for those not born in Finland the continent of origin and the year of immigration to Finland, previous AIDS-defining illnesses, hepatitis C antibodies and smoking status at the end of follow up. For each PAP smear, the date, the result according to Bethesda classification, current use of antiretroviral treatment, the most recent CD4 count and viral load were collected. An undetectable HIV load was defined as <50 copies/mL.
Key Message
PAP smear findings have improved substantially in women with well-controlled HIV. We found that women with low-risk for squamous intraepithelial lesion can be identified. They can be screened for squamous intraepithelial lesion similar to HIV-negative women. 
Statistical analyses
We studied the prevalence of cytological SIL and compared the proportions of different categories of cervical atypia at different time points during the study period. We also compared the findings connected with each individual's first and last PAP smears.
We combined LSIL, ASC-H and HSIL as any SIL for risk-factor analyses. Logistic regression analysis for binominal dependent variables was used for assessing risk factors for ever having SIL using generalized estimating equations, which take into account multiple observations of each patient. We also evaluated the risk of any future SIL in patients having their first two smears graded normal compared with those with abnormalities in the first 2 years. R language (16) was used for generalized estimating equations analyses, and IBM SPSS version 21.0 (IBM Corp., Chicago, IL, USA) for other analyses.
Ethical approval
Permission to carry out the study was granted by the Hospital District of Helsinki and Uusimaa ( §3/ 29.01.2014). According to Finnish legislation, ethics committee approval and informed consent are not required for this type of register study.
Results

Study participants
Altogether, 369 women were included in the study (Table 1) . They had acquired HIV mainly via sexual intercourse, were in their early 30s when diagnosed and had no AIDS defining diagnoses. Half of them were born in Finland and at the end of the study 33% of them smoked regularly.
The median follow-up time was 7 years [interquartile range (IQR) 4-11) and the median number of PAP 389 women attended HIV clinic during [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] One woman was excluded because of a previous ICC Seven women did not attend the screening program during the study or after it but are still followed at the HIV clinic
Twelve women did not attend the screening program during the study but have attended screening after the study with no SIL 369 women attended PAP smear screening program and were included in the study smears was five . Almost half of the participants (47%) attended screening in more than 90% of the study years, 65% attended in more than 75% of the study years and 88% attended in at least half of the study years.
SIL prevalence
In total, 2033 PAP smears were collected during the study period. (Figure 2, lower panel) .
Of the individual first PAP smear findings, 59.6% were normal, 10.3% displayed LSIL and 2.7% HSIL. At the time of the first PAP smear the median CD4 (IQR) count was 435 (299-616) cells/lL and 51.5% of the women were on cART; 39.1% of all women and 75.3% of women on ART had an undetectable viral load (Figure 3) .
At the time of each individual's last PAP-smear, 90.0% of the findings displayed normal results, 2.5% had LSIL and 0.3% had HSIL. At this time, 86.3% of the participants were on cART, and 80.7% of all women and 93.1% of women on cART had an undetectable viral load. The median (IQR) CD4 count was 565 (441-756) cells/lL ( Figure 3) .
No cases of carcinoma in situ were found during the study period. One participant was diagnosed with ICC (microinvasive carcinoma) 6 months after her HIV diagnosis, with HSIL findings in her first PAP smear.
Risk factors of SIL (combined LSIL, ASC-H and HSIL)
Both patient-related factors (origin, prior AIDS, transmission route, hepatitis C antibodies and smoking history) as well as factors related to each PAP smear specimen (CD4 count and viral load preceding the smear, cART status, age and year of sampling) were analyzed ( Table 2) .
In univariate analysis the main patient-related risk factor associated with ever having SIL was an African origin. The most important PAP smear-related risk factors as regards SIL were a viral load of >1000 copies/mL and not having cART at the time of the PAP smear. Factors predicting a lower prevalence of SIL in univariate analysis were a history of the two-first PAP smears with normal findings, a CD4 count of >500 cells/lL, year of sampling 2010-2013 as compared with 2002-2005 and age >30 years.
In a multivariate analysis a preceding viral load of >1000 copies/mL remained a strong risk factor of SIL. Having the two-first PAP smears with normal findings and a preceding CD4 count of >500 cells/lL were predictive of a low risk of SIL.
Discussion
In the present study the prevalence of cervical cytological SIL declined markedly among women living with HIV during the study years. At the same time the proportion of patients receiving cART, having an undetectable viral load and normal CD4 counts increased significantly. The proportion of normal findings (90%) among the lasttaken individual PAP smear approached that in the general population (i.e. 93%) (17) . The prevalence of cervical cytological abnormalities was significantly lower in 2002-2013 than in 1995-2002 at our institution (18) . The main protective factors for not developing SIL during the follow-up period were a history of normal cytological findings in the first two consecutive PAP smears, use of cART with good virological control, and a CD4 count exceeding 500 cells/lL. Using these patient characteristics one could possibly identify women living with HIV with a low risk of SIL, who might be monitored safely with less frequent than annual PAP screening.
Conflicting results concerning the effects of cART on the risk of SIL have been published (8, 19, 20) . However, in recent studies the use of cART has been linked to decreasing incidence and prevalence of SIL (5, 21, 22) . The present data are in line with these results. The use of modern cART and its earlier initiation in recent years diminishes the time spent with a low CD4 count, which may explain in part the conflicting results. Since the START trial proved the benefits of early initiation of cART (23), a decreasing number of women living with HIV will be monitored without the use of antiretroviral therapy in the developed world. This is likely to further reduce the incidence and prevalence of SIL among them. As ICC develops through multiple steps it may take decades to verify such a decrease in its incidence. Our data support the new European AIDS Clinical Society and DHHS guidelines recommending PAP smear screening every 3 years in women with no major risk factors. This will help to reduce the cost of care and probably also lessen the stigma associated with annual testing. The DHHS guidelines recommend co-testing (PAP smear together with HPV-DNA testing) to identify women for less frequent screening. The present results suggest that identification of these women may be feasible even without HPV-DNA testing. On the other hand, the proportion of late presenters has remained stable in many countries (24) and these women may remain at an increased risk of HPV-related cervical changes as well as those women with a poor treatment response to cART. The resources set aside should be focused on women with risk factors of SIL who remain at increased risk of progression to high-grade abnormalities and who should be screened annually.
Regardless of the screening interval, adherence to the screening remains an important factor. In the current study, all women were invited to annual screening visits as part of the overall HIV-management protocol. In cases of missed appointments, remainder invitations were sent. A recent study carried out in Denmark (25) showed that even if the importance of cervical screening is emphasized at an HIV clinic, women have relatively poor adherence to PAP-smear screening if they have to arrange it by themselves. Of note, in the Danish study, only HIVinfected women with good adherence to their screening program had PAP-smear results similar to those of HIVnegative women (22) . Thus, incorporating cervical screening in the routine care of women living with HIV seems to be essential to obtain encouraging results such as those presented here.
The limitations of our study include a relatively small sample size and its retrospective nature. The retrospective setting may, however, better reflect the real-life situation, since clinical studies and prospective programs tend to lead to overestimation of adherence to both the use of cART and attendance at PAP screening.
In this study we provide additional evidence that women on cART with good clinical responses and undergoing systematic cervical screening mostly have normal PAP smear findings with a lower risk of progressing to clinically significant cytological abnormalities and ICC than previously expected. After two consecutive normal PAP smear findings, it appears safe to screen these women every 3 years even without HPV-DNA testing. Since risk evaluation requires both HIV-related and PAP smearrelated information, good collaboration between HIV specialists and gynecologists is required to identify these women correctly. The data are important when individualizing care and follow up for women living with HIV.
